Samsung Biologics has appointed John Rim as its president and chief executive officer. The appointment was made effective immediately and formalized via the company’s board of directors meeting today.
 
Prior to being appointed CEO, Mr. Rim served as executive vice president at Samsung Biologics for the past three years and was a key senior leadership contributor in driving the company’s success through a strong focus on client satisfaction and global business acumen. He was also instrumental in rapidly expanding the manufacturing portfolio across Samsung Biologics and for the continuous operational excellence in Plant 3, the world’s largest manufacturing capacity at a single site. As CEO, Mr. Rim will continue to serve on the company’s board as an inside director offering his in-depth industry experience and global background.
 
Prior to joining Samsung Biologics in 2018, Mr. Rim worked for Genentech/Roche in a variety of senior global leadership roles in technical operations, product development, and research and development in the U.S. and Europe. He has also held senior leadership roles with Astellas Pharmaceuticals in general management, sales and marketing, technical operations, customer service, business development, and strategic planning. Mr. Rim has over 30 years’ experience in the biopharmaceutical industry and began his career as a management consultant with Booz, Allen & Hamilton consulting to pharmaceutical companies in the U.S. and Europe. 
 
“I am deeply grateful and excited by the opportunity to lead Samsung Biologics into the next decade,” said Mr. Rim. “This is an extraordinary company, unparalleled in its phenomenal growth and dedication to client satisfaction, made possible by the company’s unrelenting vision and passion, and business execution by great people whom I will have the privilege to lead as CEO.”
 
Samsung Biologics has shown strong performance throughout the year with a continuous increase in sales volume across all plants, stable business and supply management, and global business expansion including the opening of its first U.S. CDO R&D Center in San Francisco, CA. The company also recently commenced construction of its fourth plant, which is expected to further boost the company’s competitiveness in serving the growing global demand for CDMO scale and flexibility.